CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research methodology
1.4.1. Primary research
1.4.2. Secondary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top impacting factors
3.2.2. Top investment pockets
3.3. Porter’s five forces analysis
3.3.1. Moderate bargaining power of suppliers
3.3.2. Low threat of new entrants
3.3.3. Low threat of substitutes
3.3.4. Low intensity of rivalry
3.3.5. Low bargaining power of buyers
3.4. Market dynamics
3.4.1. Drivers
3.4.1.1. Rise in incidences of bacterial infections
3.4.1.2. Availability of generic medications
3.4.1.3. Significant demand for macrolides from emerging countries
3.4.2. Restraints
3.4.2.1. Rise in antimicrobial resistance
3.4.2.2. Side effects associated with macrolide antibiotics
3.4.3. Opportunities
3.4.3.1. Rise in investments in research and development activities
CHAPTER 4: MACROLIDE ANTIBIOTICS MARKET, BY DRUG TYPE
4.1. Overview
4.1.1. Market size and forecast
4.2. Azithromycin
4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market share analysis by country
4.3. Erythromycin
4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market share analysis by country
4.4. Others
4.4.1. Key market trends, growth factors and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market share analysis by country
CHAPTER 5: MACROLIDE ANTIBIOTICS MARKET, BY ROUTE OF ADMINISTRATION
5.1. Overview
5.1.1. Market size and forecast
5.2. Oral
5.2.1. Key market trends, growth factors and opportunities
5.2.2. Market size and forecast, by region
5.2.3. Market share analysis by country
5.3. Parenteral
5.3.1. Key market trends, growth factors and opportunities
5.3.2. Market size and forecast, by region
5.3.3. Market share analysis by country
5.4. Others
5.4.1. Key market trends, growth factors and opportunities
5.4.2. Market size and forecast, by region
5.4.3. Market share analysis by country
CHAPTER 6: MACROLIDE ANTIBIOTICS MARKET, BY INDICATION
6.1. Overview
6.1.1. Market size and forecast
6.2. Respiratory Tract Infections
6.2.1. Key market trends, growth factors and opportunities
6.2.2. Market size and forecast, by region
6.2.3. Market share analysis by country
6.3. Skin Infections
6.3.1. Key market trends, growth factors and opportunities
6.3.2. Market size and forecast, by region
6.3.3. Market share analysis by country
6.4. Sexually Transmitted Infections
6.4.1. Key market trends, growth factors and opportunities
6.4.2. Market size and forecast, by region
6.4.3. Market share analysis by country
6.5. Gastrointestinal Infections
6.5.1. Key market trends, growth factors and opportunities
6.5.2. Market size and forecast, by region
6.5.3. Market share analysis by country
6.6. Others
6.6.1. Key market trends, growth factors and opportunities
6.6.2. Market size and forecast, by region
6.6.3. Market share analysis by country
CHAPTER 7: MACROLIDE ANTIBIOTICS MARKET, BY DISTRIBUTION CHANNEL
7.1. Overview
7.1.1. Market size and forecast
7.2. Hospital Pharmacies
7.2.1. Key market trends, growth factors and opportunities
7.2.2. Market size and forecast, by region
7.2.3. Market share analysis by country
7.3. Drug Stores and Retail Pharmacies
7.3.1. Key market trends, growth factors and opportunities
7.3.2. Market size and forecast, by region
7.3.3. Market share analysis by country
7.4. Online Providers
7.4.1. Key market trends, growth factors and opportunities
7.4.2. Market size and forecast, by region
7.4.3. Market share analysis by country
CHAPTER 8: MACROLIDE ANTIBIOTICS MARKET, BY REGION
8.1. Overview
8.1.1. Market size and forecast By Region
8.2. North America
8.2.1. Key market trends, growth factors and opportunities
8.2.2. Market size and forecast, by Drug Type
8.2.3. Market size and forecast, by Route of Administration
8.2.4. Market size and forecast, by Indication
8.2.5. Market size and forecast, by Distribution Channel
8.2.6. Market size and forecast, by country
8.2.6.1. U.S.
8.2.6.1.1. Market size and forecast, by Drug Type
8.2.6.1.2. Market size and forecast, by Route of Administration
8.2.6.1.3. Market size and forecast, by Indication
8.2.6.1.4. Market size and forecast, by Distribution Channel
8.2.6.2. Canada
8.2.6.2.1. Market size and forecast, by Drug Type
8.2.6.2.2. Market size and forecast, by Route of Administration
8.2.6.2.3. Market size and forecast, by Indication
8.2.6.2.4. Market size and forecast, by Distribution Channel
8.2.6.3. Mexico
8.2.6.3.1. Market size and forecast, by Drug Type
8.2.6.3.2. Market size and forecast, by Route of Administration
8.2.6.3.3. Market size and forecast, by Indication
8.2.6.3.4. Market size and forecast, by Distribution Channel
8.3. Europe
8.3.1. Key market trends, growth factors and opportunities
8.3.2. Market size and forecast, by Drug Type
8.3.3. Market size and forecast, by Route of Administration
8.3.4. Market size and forecast, by Indication
8.3.5. Market size and forecast, by Distribution Channel
8.3.6. Market size and forecast, by country
8.3.6.1. Germany
8.3.6.1.1. Market size and forecast, by Drug Type
8.3.6.1.2. Market size and forecast, by Route of Administration
8.3.6.1.3. Market size and forecast, by Indication
8.3.6.1.4. Market size and forecast, by Distribution Channel
8.3.6.2. France
8.3.6.2.1. Market size and forecast, by Drug Type
8.3.6.2.2. Market size and forecast, by Route of Administration
8.3.6.2.3. Market size and forecast, by Indication
8.3.6.2.4. Market size and forecast, by Distribution Channel
8.3.6.3. UK
8.3.6.3.1. Market size and forecast, by Drug Type
8.3.6.3.2. Market size and forecast, by Route of Administration
8.3.6.3.3. Market size and forecast, by Indication
8.3.6.3.4. Market size and forecast, by Distribution Channel
8.3.6.4. Italy
8.3.6.4.1. Market size and forecast, by Drug Type
8.3.6.4.2. Market size and forecast, by Route of Administration
8.3.6.4.3. Market size and forecast, by Indication
8.3.6.4.4. Market size and forecast, by Distribution Channel
8.3.6.5. Spain
8.3.6.5.1. Market size and forecast, by Drug Type
8.3.6.5.2. Market size and forecast, by Route of Administration
8.3.6.5.3. Market size and forecast, by Indication
8.3.6.5.4. Market size and forecast, by Distribution Channel
8.3.6.6. Rest of Europe
8.3.6.6.1. Market size and forecast, by Drug Type
8.3.6.6.2. Market size and forecast, by Route of Administration
8.3.6.6.3. Market size and forecast, by Indication
8.3.6.6.4. Market size and forecast, by Distribution Channel
8.4. Asia-Pacific
8.4.1. Key market trends, growth factors and opportunities
8.4.2. Market size and forecast, by Drug Type
8.4.3. Market size and forecast, by Route of Administration
8.4.4. Market size and forecast, by Indication
8.4.5. Market size and forecast, by Distribution Channel
8.4.6. Market size and forecast, by country
8.4.6.1. Japan
8.4.6.1.1. Market size and forecast, by Drug Type
8.4.6.1.2. Market size and forecast, by Route of Administration
8.4.6.1.3. Market size and forecast, by Indication
8.4.6.1.4. Market size and forecast, by Distribution Channel
8.4.6.2. China
8.4.6.2.1. Market size and forecast, by Drug Type
8.4.6.2.2. Market size and forecast, by Route of Administration
8.4.6.2.3. Market size and forecast, by Indication
8.4.6.2.4. Market size and forecast, by Distribution Channel
8.4.6.3. India
8.4.6.3.1. Market size and forecast, by Drug Type
8.4.6.3.2. Market size and forecast, by Route of Administration
8.4.6.3.3. Market size and forecast, by Indication
8.4.6.3.4. Market size and forecast, by Distribution Channel
8.4.6.4. Australia
8.4.6.4.1. Market size and forecast, by Drug Type
8.4.6.4.2. Market size and forecast, by Route of Administration
8.4.6.4.3. Market size and forecast, by Indication
8.4.6.4.4. Market size and forecast, by Distribution Channel
8.4.6.5. South Korea
8.4.6.5.1. Market size and forecast, by Drug Type
8.4.6.5.2. Market size and forecast, by Route of Administration
8.4.6.5.3. Market size and forecast, by Indication
8.4.6.5.4. Market size and forecast, by Distribution Channel
8.4.6.6. Rest of Asia-Pacific
8.4.6.6.1. Market size and forecast, by Drug Type
8.4.6.6.2. Market size and forecast, by Route of Administration
8.4.6.6.3. Market size and forecast, by Indication
8.4.6.6.4. Market size and forecast, by Distribution Channel
8.5. LAMEA
8.5.1. Key market trends, growth factors and opportunities
8.5.2. Market size and forecast, by Drug Type
8.5.3. Market size and forecast, by Route of Administration
8.5.4. Market size and forecast, by Indication
8.5.5. Market size and forecast, by Distribution Channel
8.5.6. Market size and forecast, by country
8.5.6.1. Brazil
8.5.6.1.1. Market size and forecast, by Drug Type
8.5.6.1.2. Market size and forecast, by Route of Administration
8.5.6.1.3. Market size and forecast, by Indication
8.5.6.1.4. Market size and forecast, by Distribution Channel
8.5.6.2. Saudi Arabia
8.5.6.2.1. Market size and forecast, by Drug Type
8.5.6.2.2. Market size and forecast, by Route of Administration
8.5.6.2.3. Market size and forecast, by Indication
8.5.6.2.4. Market size and forecast, by Distribution Channel
8.5.6.3. South Africa
8.5.6.3.1. Market size and forecast, by Drug Type
8.5.6.3.2. Market size and forecast, by Route of Administration
8.5.6.3.3. Market size and forecast, by Indication
8.5.6.3.4. Market size and forecast, by Distribution Channel
8.5.6.4. Rest of LAMEA
8.5.6.4.1. Market size and forecast, by Drug Type
8.5.6.4.2. Market size and forecast, by Route of Administration
8.5.6.4.3. Market size and forecast, by Indication
8.5.6.4.4. Market size and forecast, by Distribution Channel
CHAPTER 9: COMPETITIVE LANDSCAPE
9.1. Introduction
9.2. Top winning strategies
9.3. Product mapping of top 10 player
9.4. Competitive dashboard
9.5. Competitive heatmap
9.6. Top player positioning, 2022
CHAPTER 10: COMPANY PROFILES
10.1. Abbott Laboratories
10.1.1. Company overview
10.1.2. Key executives
10.1.3. Company snapshot
10.1.4. Operating business segments
10.1.5. Product portfolio
10.1.6. Business performance
10.2. Pfizer Inc.
10.2.1. Company overview
10.2.2. Key executives
10.2.3. Company snapshot
10.2.4. Operating business segments
10.2.5. Product portfolio
10.2.6. Business performance
10.3. Alkem Laboratories Ltd.
10.3.1. Company overview
10.3.2. Key executives
10.3.3. Company snapshot
10.3.4. Operating business segments
10.3.5. Product portfolio
10.3.6. Business performance
10.4. Sun Pharmaceutical Industries Limited
10.4.1. Company overview
10.4.2. Key executives
10.4.3. Company snapshot
10.4.4. Operating business segments
10.4.5. Product portfolio
10.4.6. Business performance
10.5. Teva Pharmaceutical Industries Limited
10.5.1. Company overview
10.5.2. Key executives
10.5.3. Company snapshot
10.5.4. Operating business segments
10.5.5. Product portfolio
10.5.6. Business performance
10.5.7. Key strategic moves and developments
10.6. Wellona Pharma Private Limited.
10.6.1. Company overview
10.6.2. Key executives
10.6.3. Company snapshot
10.6.4. Operating business segments
10.6.5. Product portfolio
10.7. Bristol Laboratories Ltd.
10.7.1. Company overview
10.7.2. Key executives
10.7.3. Company snapshot
10.7.4. Operating business segments
10.7.5. Product portfolio
10.8. Crescent Pharma Limited
10.8.1. Company overview
10.8.2. Key executives
10.8.3. Company snapshot
10.8.4. Operating business segments
10.8.5. Product portfolio
10.9. Merck & Co., Inc.
10.9.1. Company overview
10.9.2. Key executives
10.9.3. Company snapshot
10.9.4. Operating business segments
10.9.5. Product portfolio
10.9.6. Business performance
10.9.7. Key strategic moves and developments
10.10. Zydus Lifesciences Limited
10.10.1. Company overview
10.10.2. Key executives
10.10.3. Company snapshot
10.10.4. Operating business segments
10.10.5. Product portfolio
10.10.6. Business performance
10.10.7. Key strategic moves and developments
TABLE 01. GLOBAL MACROLIDE ANTIBIOTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 02. MACROLIDE ANTIBIOTICS MARKET FOR AZITHROMYCIN, BY REGION, 2022-2032 ($MILLION)
TABLE 03. MACROLIDE ANTIBIOTICS MARKET FOR ERYTHROMYCIN, BY REGION, 2022-2032 ($MILLION)
TABLE 04. MACROLIDE ANTIBIOTICS MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
TABLE 05. GLOBAL MACROLIDE ANTIBIOTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 06. MACROLIDE ANTIBIOTICS MARKET FOR ORAL, BY REGION, 2022-2032 ($MILLION)
TABLE 07. MACROLIDE ANTIBIOTICS MARKET FOR PARENTERAL, BY REGION, 2022-2032 ($MILLION)
TABLE 08. MACROLIDE ANTIBIOTICS MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
TABLE 09. GLOBAL MACROLIDE ANTIBIOTICS MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 10. MACROLIDE ANTIBIOTICS MARKET FOR RESPIRATORY TRACT INFECTIONS, BY REGION, 2022-2032 ($MILLION)
TABLE 11. MACROLIDE ANTIBIOTICS MARKET FOR SKIN INFECTIONS, BY REGION, 2022-2032 ($MILLION)
TABLE 12. MACROLIDE ANTIBIOTICS MARKET FOR SEXUALLY TRANSMITTED INFECTIONS, BY REGION, 2022-2032 ($MILLION)
TABLE 13. MACROLIDE ANTIBIOTICS MARKET FOR GASTROINTESTINAL INFECTIONS, BY REGION, 2022-2032 ($MILLION)
TABLE 14. MACROLIDE ANTIBIOTICS MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
TABLE 15. GLOBAL MACROLIDE ANTIBIOTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 16. MACROLIDE ANTIBIOTICS MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2022-2032 ($MILLION)
TABLE 17. MACROLIDE ANTIBIOTICS MARKET FOR DRUG STORES AND RETAIL PHARMACIES, BY REGION, 2022-2032 ($MILLION)
TABLE 18. MACROLIDE ANTIBIOTICS MARKET FOR ONLINE PROVIDERS, BY REGION, 2022-2032 ($MILLION)
TABLE 19. MACROLIDE ANTIBIOTICS MARKET, BY REGION, 2022-2032 ($MILLION)
TABLE 20. NORTH AMERICA MACROLIDE ANTIBIOTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 21. NORTH AMERICA MACROLIDE ANTIBIOTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 22. NORTH AMERICA MACROLIDE ANTIBIOTICS MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 23. NORTH AMERICA MACROLIDE ANTIBIOTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 24. NORTH AMERICA MACROLIDE ANTIBIOTICS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 25. U.S. MACROLIDE ANTIBIOTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 26. U.S. MACROLIDE ANTIBIOTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 27. U.S. MACROLIDE ANTIBIOTICS MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 28. U.S. MACROLIDE ANTIBIOTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 29. CANADA MACROLIDE ANTIBIOTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 30. CANADA MACROLIDE ANTIBIOTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 31. CANADA MACROLIDE ANTIBIOTICS MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 32. CANADA MACROLIDE ANTIBIOTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 33. MEXICO MACROLIDE ANTIBIOTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 34. MEXICO MACROLIDE ANTIBIOTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 35. MEXICO MACROLIDE ANTIBIOTICS MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 36. MEXICO MACROLIDE ANTIBIOTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 37. EUROPE MACROLIDE ANTIBIOTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 38. EUROPE MACROLIDE ANTIBIOTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 39. EUROPE MACROLIDE ANTIBIOTICS MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 40. EUROPE MACROLIDE ANTIBIOTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 41. EUROPE MACROLIDE ANTIBIOTICS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 42. GERMANY MACROLIDE ANTIBIOTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 43. GERMANY MACROLIDE ANTIBIOTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 44. GERMANY MACROLIDE ANTIBIOTICS MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 45. GERMANY MACROLIDE ANTIBIOTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 46. FRANCE MACROLIDE ANTIBIOTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 47. FRANCE MACROLIDE ANTIBIOTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 48. FRANCE MACROLIDE ANTIBIOTICS MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 49. FRANCE MACROLIDE ANTIBIOTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 50. UK MACROLIDE ANTIBIOTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 51. UK MACROLIDE ANTIBIOTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 52. UK MACROLIDE ANTIBIOTICS MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 53. UK MACROLIDE ANTIBIOTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 54. ITALY MACROLIDE ANTIBIOTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 55. ITALY MACROLIDE ANTIBIOTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 56. ITALY MACROLIDE ANTIBIOTICS MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 57. ITALY MACROLIDE ANTIBIOTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 58. SPAIN MACROLIDE ANTIBIOTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 59. SPAIN MACROLIDE ANTIBIOTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 60. SPAIN MACROLIDE ANTIBIOTICS MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 61. SPAIN MACROLIDE ANTIBIOTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 62. REST OF EUROPE MACROLIDE ANTIBIOTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 63. REST OF EUROPE MACROLIDE ANTIBIOTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 64. REST OF EUROPE MACROLIDE ANTIBIOTICS MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 65. REST OF EUROPE MACROLIDE ANTIBIOTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 66. ASIA-PACIFIC MACROLIDE ANTIBIOTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 67. ASIA-PACIFIC MACROLIDE ANTIBIOTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 68. ASIA-PACIFIC MACROLIDE ANTIBIOTICS MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 69. ASIA-PACIFIC MACROLIDE ANTIBIOTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 70. ASIA-PACIFIC MACROLIDE ANTIBIOTICS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 71. JAPAN MACROLIDE ANTIBIOTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 72. JAPAN MACROLIDE ANTIBIOTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 73. JAPAN MACROLIDE ANTIBIOTICS MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 74. JAPAN MACROLIDE ANTIBIOTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 75. CHINA MACROLIDE ANTIBIOTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 76. CHINA MACROLIDE ANTIBIOTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 77. CHINA MACROLIDE ANTIBIOTICS MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 78. CHINA MACROLIDE ANTIBIOTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 79. INDIA MACROLIDE ANTIBIOTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 80. INDIA MACROLIDE ANTIBIOTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 81. INDIA MACROLIDE ANTIBIOTICS MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 82. INDIA MACROLIDE ANTIBIOTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 83. AUSTRALIA MACROLIDE ANTIBIOTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 84. AUSTRALIA MACROLIDE ANTIBIOTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 85. AUSTRALIA MACROLIDE ANTIBIOTICS MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 86. AUSTRALIA MACROLIDE ANTIBIOTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 87. SOUTH KOREA MACROLIDE ANTIBIOTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 88. SOUTH KOREA MACROLIDE ANTIBIOTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 89. SOUTH KOREA MACROLIDE ANTIBIOTICS MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 90. SOUTH KOREA MACROLIDE ANTIBIOTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 91. REST OF ASIA-PACIFIC MACROLIDE ANTIBIOTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 92. REST OF ASIA-PACIFIC MACROLIDE ANTIBIOTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 93. REST OF ASIA-PACIFIC MACROLIDE ANTIBIOTICS MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 94. REST OF ASIA-PACIFIC MACROLIDE ANTIBIOTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 95. LAMEA MACROLIDE ANTIBIOTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 96. LAMEA MACROLIDE ANTIBIOTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 97. LAMEA MACROLIDE ANTIBIOTICS MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 98. LAMEA MACROLIDE ANTIBIOTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 99. LAMEA MACROLIDE ANTIBIOTICS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 100. BRAZIL MACROLIDE ANTIBIOTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 101. BRAZIL MACROLIDE ANTIBIOTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 102. BRAZIL MACROLIDE ANTIBIOTICS MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 103. BRAZIL MACROLIDE ANTIBIOTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 104. SAUDI ARABIA MACROLIDE ANTIBIOTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 105. SAUDI ARABIA MACROLIDE ANTIBIOTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 106. SAUDI ARABIA MACROLIDE ANTIBIOTICS MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 107. SAUDI ARABIA MACROLIDE ANTIBIOTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 108. SOUTH AFRICA MACROLIDE ANTIBIOTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 109. SOUTH AFRICA MACROLIDE ANTIBIOTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 110. SOUTH AFRICA MACROLIDE ANTIBIOTICS MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 111. SOUTH AFRICA MACROLIDE ANTIBIOTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 112. REST OF LAMEA MACROLIDE ANTIBIOTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 113. REST OF LAMEA MACROLIDE ANTIBIOTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 114. REST OF LAMEA MACROLIDE ANTIBIOTICS MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 115. REST OF LAMEA MACROLIDE ANTIBIOTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 116. ABBOTT LABORATORIES: KEY EXECUTIVES
TABLE 117. ABBOTT LABORATORIES: COMPANY SNAPSHOT
TABLE 118. ABBOTT LABORATORIES: PRODUCT SEGMENTS
TABLE 119. ABBOTT LABORATORIES: PRODUCT PORTFOLIO
TABLE 120. PFIZER INC.: KEY EXECUTIVES
TABLE 121. PFIZER INC.: COMPANY SNAPSHOT
TABLE 122. PFIZER INC.: PRODUCT SEGMENTS
TABLE 123. PFIZER INC.: PRODUCT PORTFOLIO
TABLE 124. ALKEM LABORATORIES LTD.: KEY EXECUTIVES
TABLE 125. ALKEM LABORATORIES LTD.: COMPANY SNAPSHOT
TABLE 126. ALKEM LABORATORIES LTD.: PRODUCT SEGMENTS
TABLE 127. ALKEM LABORATORIES LTD.: PRODUCT PORTFOLIO
TABLE 128. SUN PHARMACEUTICAL INDUSTRIES LIMITED: KEY EXECUTIVES
TABLE 129. SUN PHARMACEUTICAL INDUSTRIES LIMITED: COMPANY SNAPSHOT
TABLE 130. SUN PHARMACEUTICAL INDUSTRIES LIMITED: PRODUCT SEGMENTS
TABLE 131. SUN PHARMACEUTICAL INDUSTRIES LIMITED: PRODUCT PORTFOLIO
TABLE 132. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: KEY EXECUTIVES
TABLE 133. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: COMPANY SNAPSHOT
TABLE 134. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: PRODUCT SEGMENTS
TABLE 135. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: PRODUCT PORTFOLIO
TABLE 136. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: KEY STRATERGIES
TABLE 137. WELLONA PHARMA PRIVATE LIMITED.: KEY EXECUTIVES
TABLE 138. WELLONA PHARMA PRIVATE LIMITED.: COMPANY SNAPSHOT
TABLE 139. WELLONA PHARMA PRIVATE LIMITED.: PRODUCT SEGMENTS
TABLE 140. WELLONA PHARMA PRIVATE LIMITED.: PRODUCT PORTFOLIO
TABLE 141. BRISTOL LABORATORIES LTD.: KEY EXECUTIVES
TABLE 142. BRISTOL LABORATORIES LTD.: COMPANY SNAPSHOT
TABLE 143. BRISTOL LABORATORIES LTD.: PRODUCT SEGMENTS
TABLE 144. BRISTOL LABORATORIES LTD.: PRODUCT PORTFOLIO
TABLE 145. CRESCENT PHARMA LIMITED: KEY EXECUTIVES
TABLE 146. CRESCENT PHARMA LIMITED: COMPANY SNAPSHOT
TABLE 147. CRESCENT PHARMA LIMITED: PRODUCT SEGMENTS
TABLE 148. CRESCENT PHARMA LIMITED: PRODUCT PORTFOLIO
TABLE 149. MERCK & CO., INC.: KEY EXECUTIVES
TABLE 150. MERCK & CO., INC.: COMPANY SNAPSHOT
TABLE 151. MERCK & CO., INC.: PRODUCT SEGMENTS
TABLE 152. MERCK & CO., INC.: PRODUCT PORTFOLIO
TABLE 153. MERCK & CO., INC.: KEY STRATERGIES
TABLE 154. ZYDUS LIFESCIENCES LIMITED: KEY EXECUTIVES
TABLE 155. ZYDUS LIFESCIENCES LIMITED: COMPANY SNAPSHOT
TABLE 156. ZYDUS LIFESCIENCES LIMITED: PRODUCT SEGMENTS
TABLE 157. ZYDUS LIFESCIENCES LIMITED: PRODUCT PORTFOLIO
TABLE 158. ZYDUS LIFESCIENCES LIMITED: KEY STRATERGIES
